Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm.

Induces a slow inward sodium current, which prolongs action potential and refractory period of myocardial cells.

There should not be concomitant administration of Class Ia and Class III agents.

Trade name Corvert.

Results in successful heart rhythm control in 31-44% of patients within 90 minutes, with sustained polymorphic ventricular tachycardia in 0.9-2.5% of patients.

Results in atrial flutter are better than for atrial fibrillation.

Should not be used in patients with prolonged QT intervals.

Approximately 3% of patients who receive ibutilide develop torsades de pointes and should be monitored for 4 hours following administration of this drug.

Leave a Reply

Your email address will not be published. Required fields are marked *